Home Cart Sign in  
Chemical Structure| 130-85-8 Chemical Structure| 130-85-8
Chemical Structure| 130-85-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pamoic acidis a potent GPR35 agonist with an EC50 of 79 nM, exhibiting neuroprotective and anti-inflammatory effects.

Synonyms: Embonic Acid; NSC 40132; NSC 30188

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pamoic acid

CAS No. :130-85-8
Formula : C23H16O6
M.W : 388.37
SMILES Code : O=C(O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C4C=CC=CC4=C1
Synonyms :
Embonic Acid; NSC 40132; NSC 30188
MDL No. :MFCD00004079
InChI Key :WLJNZVDCPSBLRP-UHFFFAOYSA-N
Pubchem ID :8546

Safety of Pamoic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of Pamoic acid

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 130-85-8 ]

[ 130-85-8 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 121-44-8 ]
  • [ 130-85-8 ]
  • C46H24B2O12(2-)*2C6H15N*2H(1+) [ No CAS ]
  • 2
  • [ 130-85-8 ]
  • [ 217327-72-5 ]
  • 3
  • [ 130-85-8 ]
  • (S)-2-({4-[3-((S)-1-Carboxy-2-methyl-propylcarbamoyl)-2-hydroxy-naphthalen-1-ylmethyl]-3-hydroxy-naphthalene-2-carbonyl}-amino)-3-methyl-butyric acid [ No CAS ]
  • 4
  • [ 130-85-8 ]
  • [ 217327-74-7 ]
  • 5
  • [ 130-85-8 ]
  • (E)-(S)-4-({4-[3-((E)-(S)-3-Carboxy-1-isopropyl-allylcarbamoyl)-2-hydroxy-naphthalen-1-ylmethyl]-3-hydroxy-naphthalene-2-carbonyl}-amino)-5-methyl-hex-2-enoic acid [ No CAS ]
  • 6
  • [ 130-85-8 ]
  • (S)-2-{(S)-2-[(4-{3-[(S)-1-((S)-1-Carboxy-2-methyl-propylcarbamoyl)-2-methyl-propylcarbamoyl]-2-hydroxy-naphthalen-1-ylmethyl}-3-hydroxy-naphthalene-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyric acid [ No CAS ]
  • 7
  • [ 130-85-8 ]
  • [ 217327-73-6 ]
  • 8
  • [ 130-85-8 ]
  • [ 153495-52-4 ]
  • 9
  • [ 130-85-8 ]
  • [ 177267-85-5 ]
  • 10
  • [ 130-85-8 ]
  • [ 153495-50-2 ]
  • 11
  • [ 130-85-8 ]
  • homocalixnaphthalene [ No CAS ]
  • 12
  • [ 130-85-8 ]
  • [ 177267-86-6 ]
  • 14
  • [ 76144-81-5 ]
  • [ 130-85-8 ]
  • meldonium hydrogen pamoate [ No CAS ]
YieldReaction ConditionsOperation in experiment
In water; acetone; toluene; EXAMPLE 10 Meldonium pamoate (1 : 1 ; X H20). MELDONIUM (5. 46 G, 30 MMOL) AND PAMOIC acid (5.82 g, 15 MMOL) are mixed with water and acetone (15 + 15 ml), the formed suspension is evaporated, 30-40 ml toluene is added to the residual viscous mass, it is grated, and evaporation is repeated. If the residue is insufficiently dry, treatment with toluene is repeated. Mp. 128-133C (DECOMP.). H NMR spectrum (DMSO-d6), 8, ppm: 2.41 (2H, t, CH2COO-) ; 3.14 (2H, t, CH2N) ; 3.25 (9H, s, ME3N+) ; 4.75 (2H, s, - CH2- (PAM.)) ; 7.12 (2H, t, Harem) ; 7.26 (2H, td, HAROM) ; 7.77 (2H, d, HAROM) ; 8. 18 (2H, d, HAROM) ; 8. 35 (2H, s, Harom). Found, percent : C 62,90 ; H 5, 83 ; N 4,98. Calculated, percent: C 63,07 ; H 5, 84; N 5,07. Initially HA0 content in the sample was 1.71percent ; after 24 hours maintenance at 100percent humidity sample mass increased by 9percent due to absorbed water.
  • 15
  • [ 152459-95-5 ]
  • [ 130-85-8 ]
  • [ 862366-33-4 ]
YieldReaction ConditionsOperation in experiment
In ethanol; water;Heating / reflux; Example 10; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl] amino] phenyl]-benzamide, pamoate; A mixture of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl] amino] phenyl]-benzamide (4.94 g, 10 mmol) and 4, 4'-methylenebis [3-hydroxy-2- naphthoic acid (Fluka, Buchs, Switzerland ; 3.88 g, 10 mmol) in ethanol (50 mL) is heated. Water (25 mL) is then added. Upon cooling, the product crystallises and is filtered-off and dried to afford 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl] amino] phenyl]-benzamide, pamoate as a pale-yellow solid, having the following analytical properties: Analysis found: C, 69.12 ; H, 5.62 ; N, 10.88percent ; H20, 2.50percent. Calculated for C52H47N707-1. 26 H20 : C, 69.04 ; H, 5.52 ; N, 10.84percent ; H20, 2. 51percent.
  • 16
  • cetrorelix acetate [ No CAS ]
  • [ 130-85-8 ]
  • cetrorelix embonate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With sodium hydroxide; In water;pH 7 - 7.5;Product distribution / selectivity; In an equimolar ratio of peptide (calculated as free base) to embonic acid, an aqueous solution of embonic acid containing alkali in excess is combined with the acetate cetrorelix acetate solution, embonic acid precipitating as yellow crystals. On addition of dilute sodium hydroxide solution up to pH 7 - 7.5, the embonic acid dissolves and precipitates with the decapeptide as aqueous cetrorelix embonate salt of the molar composition peptide : embonic acid 2:1 (Mol/Mol). The precipitate is filtered off, washed with H2O and dried.
In ethanol; water;Product distribution / selectivity; The alkaline embonate solution is added to the aqueous ethanolic solution of the peptide acetate in the molar ratio peptide : embonic acid 2:1. The white precipitate is filtered off and dried. The dried precipitate is moistened with 50percent ethanol, dried in a vacuum drying cabinet and sieved. The white product contains the 2:1 peptide embonate salt (Mol/Mol). Example 5 The alkaline embonate solution is added to the aqueous ethanolic solution of the peptide acetate in the molar ratio peptide : embonic acid 1:1.6. The yellow precipitate is filtered off and dried. The dried precipitate is moistened with 50percent ethanol, dried in a vacuum drying cabinet at 35°C and sieved. The yellow product contains the 2:1 peptide embonate salt (Mol/Mol) in addition to the excess of embonic acid.
In ISOPROPYLAMIDE; water;Product distribution / selectivity; Cetrorelix acetate and embonic acid are dissolved in equimolar proportions in dimethylacetamide and the solution is dropped into water. The white precipitate of the cetrorelix embonate peptide : embonic acid 2:1 (Mol/Mol) is filtered off and dried. Example 3 Cetrorelix and embonic acid are dissolved in a molar ratio of 1:1.6 in a mixture of dimethyl acetamide and optionally water and the solution dropped into water. The yellow precipitate is filtered off and dried. The precipitate obtained is pasted with 70percent ethanol, dried at 35°C and sieved through a sieve of mesh size 80 to 125 um.
  • 17
  • [ 132539-06-1 ]
  • [ 130-85-8 ]
  • relprevv [ No CAS ]
YieldReaction ConditionsOperation in experiment
In tetrahydrofuran;Molecular sieve; Preparation 1; Preparation of 2-methyl-4-(4-methyl- 1 -piperazinvD- 10H-thieno|"2.3 - b]ri,5~|benzodiazepine pamoate (olanzapine pamoate. See for example Preparation 3 in U.S. Patent No. 6.169.084 BlVOlanzapine (3.12 g, 0.01 mole) is dissolved in tetrahydrofuran (50 mL) with heating. <strong>[130-85-8]Pamoic acid</strong> (3.88 g, 0.01 mole) is dissolved in tetrahydrofuran (100 mL) with heating. The two solutions are mixed and filtered through a pad of Celite.(R). while it is still warm. The yellow solution is transferred to a Buchi flask and evaporated under reduced pressure (bath temperature 5O0C). After about 50 mL of solvent are removed ethanol (50 mL) is introduced and evaporation continued. A further 50 mL of ethanol is introduced after a further 50 mL of solvent is collected. Evaporation is continued until crystallization commences. The crystals are collected by filtration and dried under high vacuum at 12O0C. m.p. 203-2050C.
In N,N-dimethyl-formamide; at 20℃; for 0.333333h;Product distribution / selectivity; Example 1 : Preparation of amorphous form of olanzapine pamoate[00098] <strong>[130-85-8]Pamoic acid</strong> (2.5 g, 6.4 mmol) and olanzapine (2 g, 6.4 mmol) were dissolved in dimethylformamide (DMF) (10 mL) by stirring at room temperature for 20 min. The resulting orange solution was added dropwise via dropping funnel to a 250 mL round flask containing isopropyl alcohol (IP A) (extra-dry, 100 mL) at 5°C. The obtained yellow slurry was stirred at 5°C for 3 h. The yellow-orange solid was collected by suction filtration and was washed with IPA (extra-dry (>99.9percent), 50 mL). The product was dried in a vacuum oven at 60°C. The resulting powder was analyzed by XRPD to give a pattern of olanzapine pamoate amorphous form, as shown in Figure 1.
  • 18
  • [ 132539-06-1 ]
  • [ 130-85-8 ]
  • olanzapine pamoate monohydrate [ No CAS ]
YieldReaction ConditionsOperation in experiment
97% Preparation of olanzapine pamoate monohydrate by Ammonia and HCI<strong>[130-85-8]Pamoic acid</strong> (6.2 g, 16 mmol) was mixed with water (100 ml) and aqueous ammonia (7.5g, 32mmol) to get a clear solution. Olanzapine (5.0 g, 16 mmol) was mixed with water (100ml) and aqueous hydrochloric acid (3.65 g, 32mmol) to get a clear solution. The prepared disodium pamoate solution was added into the prepared olanzapine solution at room temperature of 25- 30°C and the reaction mixture was stirred for 30 minutes at the same temperature. The resultant yellow solid was filtered, washed with water (15 ml) and dried in a vacuum oven at 40-45°C. percent Yield: 97percent
Preparation 2; Preparation of 2-methyl-4-(4-methyl-l-piperazinylV10H-thieno[2.3- biri.5~|benzodiazepine pamoate (olanzapine pamoate monohydrate, See for example Preparation 6 in U.S. Patent No. 6.169.084 BlV Into a suitable beaker equipped with a magnetic stirrer is added methyl sulfoxide(22 ml), pamoic acid (2.49 g, 6.41 mmol), and olanzapine (2.0 g, 6.40 mmol). The slurry is stirred at 20-250C to dissolve (about 20 minutes). The solution is added over 20 minutes to a 250 mL three-necked flask equipped with a mechanical stirrer and containing water (96 ml) at 4O0C. After the addition is complete, the slurry is stirred about 20 minutes at 400C, cooled to 20-25°C over about 30 minutes, filtered, and washed with water (25 ml). The product is dried in vacuo at 500C to provide the title compound (4.55g).
  • 19
  • [ 130-85-8 ]
  • [ 6640-22-8 ]
YieldReaction ConditionsOperation in experiment
With sodium hydroxide; In water; a) preparation of sodium embonate 3.88 g of embonic acid are suspended in water. While stirring, the suspension was dissolved by adding 20 ml 1N NaOH, after which the volume of the solution was adjusted to 100 ml (0.1 molar),
  • 20
  • [ 13520-78-0 ]
  • [ 130-85-8 ]
  • 2(WOCl3)(1+)*((C10H5(COO)(OH))2CH2)(2-)*2O(C2H5)2 = (WOCl3)2((C10H5(COO)(OH))2CH2)*2O(C2H5)2 [ No CAS ]
  • 21
  • [ 553-26-4 ]
  • [ 64-17-5 ]
  • [ 5743-04-4 ]
  • [ 1310-73-2 ]
  • [ 130-85-8 ]
  • ([Cd5(μ3-acetate)2(μ2-acetate)2(μ3-OH)2(pamoate)2(4,4'-bipyridyl)2]*ethanol)n [ No CAS ]
  • 22
  • [ 59803-98-4 ]
  • [ 130-85-8 ]
  • [ 1084892-10-3 ]
YieldReaction ConditionsOperation in experiment
86% In ethanol; dimethyl sulfoxide; at 20 - 65℃;Product distribution / selectivity; EXAMPLE 11; Preparation of Other Lots of Complexes Comprising Brimonidine and Selected CounterionsSeveral lots of complexes, in quantities of 1-4 grams, comprising brimonidine and selected counterions were prepared.EXAMPLE 11-1Complex Comprising Brimonidine and Pamoic AcidIn a two-liter, three-neck round bottom flask equipped with overhead stirrer, heating mantle, condenser, temperature probe, and N2 inlet, 2.0 g of brimonidine (lot BRMB-001 L08) was dissolved in ethanol (800 mL) at 65° C. <strong>[130-85-8]Pamoic acid</strong> (1.05 eq, 7.5 mL, 0.5M in DMSO) was then added. The resulting solution was stirred for 10 minutes and then cooled at 20° C./h to ambient temperature. At 50° C., precipitation of solids was observed. The mixture stirred overnight at ambient temperature and was then filtered. The solids were then dried under vacuum at ambient temperature for 72 h affording 2.872 g (86percent yield) of yellow solids (lot No. PDH-P-36(1)). XRD spectra of this material and another sample (lot JMS-A-23(1)) previously prepared are shown in FIG. 6. The spectra are consistent, indicating that the material was reproduced. A proton NMR spectrum of lot No. PDH-P-36(1) is shown in FIG. 9.
In 1-methyl-pyrrolidin-2-one; water; at 70℃;Product distribution / selectivity; EXAMPLE 9; Preparation of Brimonidine Pamoate ComplexBrimonidine and pamoic acid, at a molar ratio of 1:1, were mixed and dispersed in N-methylpyrrolidone ("NMP"). The solution of brimonidine and pamoic acid in NMP was heated while stirring to dissolve brimonidine (the final temperature, typically less than 70° C., was chosen so as not to lose significant amount of solvent). Water, as an anti-solvent, was added until the solution began to become cloudy, indicating that the complex started to precipitate. The precipitation was allow to proceed; for example, for several hours or overnight. The precipitated was filtered under vacuum, and dry solid comprising the brimonidine pamoate complex was recovered. Other solvents, known to people skilled in the art, may be used for a compound that provides the counterion to the alpha2-adrenergic agonist, as appropriate. Solubilities of brimonidine free base, brimonidine pamoate, and brimonidine tartrate in water were measured, after 11 days on a twist shaker, to be 215.1 mug/ml, 20.7 mug/ml, and 41588 mug/ml, respectively. FIGS. 1, 2, and 3 show NMR spectra of brimonidine free base, pamoic acid, and brimonidine pamoate complex, respectively. FIG. 4 shows XRD spectra of pamoic acid (bottom curve), brimonidine free base (middle curve), and simple solid mixture of brimonidine and pamoic acid (top curve). FIG. 5 shows XRD spectra of pamoic acid (bottom curve), brimonidine free base (top curve), and complex of brimonidine and pamoic acid (middle curve).
at 60 - 70℃;Product distribution / selectivity; EXAMPLE 10; Preparation of Various Complexes Comprising Brimonidine and Selected CounterionsIn this experiment, various complexes comprising Brimonidine and counterions of one of the following acids were prepared: pamoic acid, capric acid, sebacic acid, hippuric acid, naproxen, 1-hydroxy-2-naphthoic acid, palmitic acid, and stearic acid. Variations of the procedure described in the following disclosure may be made within the skill of a person of ordinary skill in the art without departing from the scope of the present invention. Brimonidine free base in a preselected solvent was heated to about 60-70° C. The organic acid in another portion of the solvent was added into the heated mixture or was included in the original mixture before heating. The heating of the combined mixture was continued for an additional period, which was not critical. In certain embodiments, an antisolvent was added to the combined mixture, preferably at a lower temperature, to effect a precipitation of the complex of brimonidine and the counterion. It may be advantageous to remove a portion of the solvent and antisolvent to assist the precipitation. In certain other embodiments, the heated combined mixture was cooled down to a lower temperature, such as room temperature (or below) to effect the precipitation of the complex of brimonidine and the counterion. The precipitate was then filtered and dried to yield the final complex. The solubility of various complexes in water at the resulting pH is shown in Table 9.
  • 23
  • [ 64-17-5 ]
  • [ 7732-18-5 ]
  • [ 5743-04-4 ]
  • [ 5144-89-8 ]
  • [ 130-85-8 ]
  • [Cd(pamoic acid)(1,10-phenanthroline)]n*0.5EtOH*0.5H2O [ No CAS ]
  • 24
  • [ 366-18-7 ]
  • [ 5970-45-6 ]
  • [ 130-85-8 ]
  • [ 1095905-74-0 ]
  • 25
  • [ 5970-45-6 ]
  • [ 5144-89-8 ]
  • [ 130-85-8 ]
  • [ 1095905-78-4 ]
  • 26
  • [ 366-18-7 ]
  • cadmium(II) nitrate tetrhydrate [ No CAS ]
  • [ 130-85-8 ]
  • [Cd(pamoic acid)(2,2'-bipyridine)2]n [ No CAS ]
  • 27
  • [ 1132073-57-4 ]
  • [ 130-85-8 ]
  • N-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-N-methyl-3-oxopropan-1-amine hemipamoate [ No CAS ]
YieldReaction ConditionsOperation in experiment
EXAMPLE 3c N-[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-N-methyl-3-oxopropan-1-amine hemipamoate The expected product is obtained by converting N-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl }-3(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-N-methyl-3-oxopropan-1-amine, obtained by returning the hydrochloride obtained in Example 3a to the base, to a salt using pamoic acid.
  • 28
  • [ 7732-18-5 ]
  • [ 7646-85-7 ]
  • 4′-(3-pyridyl)-2,2′:6′,2′′-terpyridine [ No CAS ]
  • [ 130-85-8 ]
  • [Zn(pamotate(2-))(4'-(3-pyridyl)-2,2':6',2''-terpuridine)]n*2nH2O [ No CAS ]
  • 29
  • [ 66-71-7 ]
  • [ 5743-04-4 ]
  • [ 130-85-8 ]
  • [ 1221273-08-0 ]
  • 30
  • [ 553-26-4 ]
  • [ 16986-94-0 ]
  • [ 7732-18-5 ]
  • [ 68-12-2 ]
  • [ 130-85-8 ]
  • 4,4'-bipyridinium [bis(4,4'-methylenebis(3-oxidonaphthalene-2-carboxylato)(μ-O)(DMF)2dititanate(IV)]*4DMF monohydrate [ No CAS ]
  • 31
  • [ 16986-94-0 ]
  • [ 68-12-2 ]
  • [ 130-85-8 ]
  • [bis(4-((2-carboxy-3-oxidonaphthalen-4-yl)methyl)-3-oxidonaphthalene-2-carboxylato)dititanium(IV)(μ-O)(DMF)2]*6DMF [ No CAS ]
  • 32
  • [ 59803-98-4 ]
  • [ 130-85-8 ]
  • brimonidine hemipamoate [ No CAS ]
YieldReaction ConditionsOperation in experiment
In ethanol; dimethyl sulfoxide; at 65℃; for 0.5h; Brimonidine Pamoate Polymorph Form AIn a 5 L 3-neck round bottom flask equipped with overhead stirrer, heating mantle, condenser, temperature probe, and N2 inlet, 4.8 g of brimonidine (lot 1-080085) was dissolved in ethanol (2000 mL) at 65° C. <strong>[130-85-8]Pamoic acid</strong> (1.05 eq, 19.0 mL, 0.5M in DMSO (dimethyl sulfoxide)) was then added. The resulting solution was stirred for 30 minutes at 65° C. and then cooled at 20° C./hour to ambient temperature. At the onset of the cooling profile, precipitation of solids was observed. The mixture stirred overnight at ambient temperature and was then filtered. The resulting solids were dried under vacuum at ambient temperature for 4 days before being analyzed by XRPD to confirm the solid form, designated as Form A. FIG. 1 shows an XRPD spectrum of brimonidine pamoate polymorph Form A (lot SUC-I-130(1)).In one aspect, polymorph Form A is characterized by an XRPD spectrum comprising major peaks at 2psi angles of 13.5, 20.6, 21.1, and 24.4°+/-0.2°.In another aspect, polymorph Form A is characterized by an XRPD spectrum comprising peaks at 2psi angles of 7.6, 12.2, 12.7, 13.5, 20.6, 21.1, 24.4, 26.5, and 27.7°+/-0.2°.1H NMR analysis of this material showed approximately 3.7 wt percent residual ethanol and a 0.5:1 pamoate to brimonidine ratio confirming the formation of a hemi-pamoate salt of brimonidine. FIG. 2 shows an NMR spectrum for brimonidine pamoate polymorph Form A (lot SUC-I-130(1).Thermal analysis of Form A showed a single DSC endotherm at 221° C. (see FIG. 3) attributed to the melting of the salt and 3.5percent TGA weight loss through 190° C. (see FIG. 4) attributed to the removal of ethanol.FIG. 5 shows a Raman spectroscopy spectrum of Form A (lot SUC-I-130(1), to be compared to Raman spectra of other polymorphs.In one aspect, polymorph Form A is characterized by a Raman spectroscopy spectrum comprising major peaks at 1340.8, 1352.4, 1365.8, 1402.0, and 1460.3 cm-1.In another aspect, polymorph Form A is characterized by a Raman spectroscopy spectrum comprising peaks at 135.4, 169.3, 189.2, 233.0, 326.9, 547.9, 693.3, 719.4, 838.3, 938.3, 1031.1, 1197.6, 1252.4, 1270.2, 1340.8, 1352.4, 1365.8, 1402.0, 1460.3, 1549.0, 1556.0, and 1571.0 cm-1.Moisture sorption analysis of Form A showed this hemi-pamoate polymorph to be slightly hygroscopic, adsorbing 2.2 percent by weight ("wt percent") water at 60 percent relative humidity ("percent RH") and 2.5 wt percent water at 90percent RH. Upon desorption, no hysteresis or indication of hydrate formation was observed. XRPD analysis of the solids following moisture sorption analysis afforded a diffraction pattern which was consistent with the Form A starting material, indicating no polymorphic form conversion had occurred during the experiment.
  • 33
  • [ 553-26-4 ]
  • cobalt(II) nitrate hexahydrate [ No CAS ]
  • [ 130-85-8 ]
  • [ 1238846-20-2 ]
  • 34
  • [ 110-86-1 ]
  • manganese (II) sulfate monohydrate [ No CAS ]
  • [ 130-85-8 ]
  • [Mn2((pamoic acid)(-2H))2(pyridine)6(water)2]n*2n(pyridine) [ No CAS ]
  • 35
  • [ 553-26-4 ]
  • nickel(II) nitrate hexahydrate [ No CAS ]
  • [ 75-05-8 ]
  • [ 130-85-8 ]
  • [Ni((pamoic acid)(-2H))(4,4'-bipyridine)(water)2]n*2n(acetonitrile) [ No CAS ]
 

Historical Records

Categories